News

In this analysis, the investigators evaluated the temporal increase in hair shedding amounts following topical minoxidil utilization.

The FDA approval of diazoxide choline extended-release tablets (Vykat XR) was announced on March 26, 2025.

A meta-analysis of 27 trials found no increased risk of suicide or self-harm with GLP-1 RAs, supporting their safety for diabetes and obesity management.

Tabrizian discusses neoadjuvant immunotherapy for HCC, describing its success in the adjuvant setting but uncertainties about its use before transplant.

A phase 1 study found neffy nasal spray provides effective epinephrine absorption in children, supporting its role as a needle-free anaphylaxis treatment.

This quiz, the first in 4 part series, focuses on pivotal data from the INTEGUMENT trials in atopic dermatitis.

A Q2 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for dupilumab, pz-cel, ketamine, clesrovimab, and more!

Dara describes similarities between drug-induced autoimmune-like hepatitis and idiopathic autoimmune hepatitis, as well as how to differentiate them.

Despite low food allergy prevalence in adults (0.31%), anaphylaxis remains common, highlighting the need for better diagnosis and emergency treatment.

This analysis highlights the increased risk among those with psoriasis for developing such ocular conditions as conjunctivitis, dry eye, and conjunctival hyperemia.

A study found many anaphylaxis patients didn’t receive adrenaline, the first-line treatment. Adrenaline use correlated with better outcomes in adults and children.

Martinez explains the benefit of IBAT inhibitors for improving pruritus in children with Alagille syndrome and PFIC.

Caution may be needed when prescribing 5 mg of oral minoxidil to patients with alopecia and pericardial risk factors such as systemic lupus erythematosus.

The pivotal trial investigating sozinibercept combination therapy failed to meet the primary endpoint of mean change in BCVA at 52 weeks.

The approval is based on data from the phase 3 EAGLE-2 and EAGLE-3 trials.

Goel describes the clinical impact of having 2 newly approved second-line PBC therapies and looks ahead to what’s next and where more research is needed.

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

Lammert describes the lack of developments in autoimmune hepatitis care over the past several decades and points to what might be next in disease management.

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.

These data highlight the comparability of Humira, the adalimumab originator, to the drug’s biosimilars in terms of efficacy in treating psoriasis.

Positive topline results from PORTOLA show treatment with zetomipzomib resulted in steroid-sparing biochemical remissions in AIH.

New study highlights discrepancies in anaphylaxis severity scoring, emphasizing the need for a unified classification to improve treatment.

Mitchell reviews FDA-approved drugs for reducing alcohol use, which ones can be used in patients with liver disease, and other therapies on the horizon.

FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia over IS.

Khandelwal discusses advancements in intraocular lens (IOL) categories and the patient's role in choosing more innovative options.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

Schilsky describes lingering challenges and unmet needs in Wilson disease and highlights recent innovations in monitoring and diagnosis.